Exact Mass: 523.1518954000001
Exact Mass Matches: 523.1518954000001
Found 260 metabolites which its exact mass value is equals to given mass value 523.1518954000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Deoxyribonucleic acid
Hapten
C26H26ClN5O3S (523.1444796000001)
Penfluridol
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml[1][2][3][4].
PENFLURIDOL
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml[1][2][3][4].
Anhydropseudophlegmacin-9,10-quinone-3-amino-8-O-methyl ether
4-(hydroxymethyl)phenyl 5-O-nicotinyl-beta-D-apiofuranosyl(1->2)-beta-D-glucopyranoside|cucurbitoside L
Cys Cys Ile Trp
C23H33N5O5S2 (523.1923008000001)
Cys Cys Leu Trp
C23H33N5O5S2 (523.1923008000001)
Cys Cys Trp Ile
C23H33N5O5S2 (523.1923008000001)
Cys Cys Trp Leu
C23H33N5O5S2 (523.1923008000001)
Cys Asp Met Arg
Cys Asp Arg Met
Cys Asp Thr Trp
Cys Asp Trp Thr
Cys Glu Ser Trp
Cys Glu Trp Ser
Cys His His Gln
Cys His Gln His
Cys Ile Cys Trp
C23H33N5O5S2 (523.1923008000001)
Cys Ile Trp Cys
C23H33N5O5S2 (523.1923008000001)
Cys Leu Cys Trp
C23H33N5O5S2 (523.1923008000001)
Cys Leu Trp Cys
C23H33N5O5S2 (523.1923008000001)
Cys Met Asp Arg
Cys Met Arg Asp
Cys Gln His His
Cys Arg Asp Met
Cys Arg Met Asp
Cys Ser Glu Trp
Cys Ser Trp Glu
Cys Thr Asp Trp
Cys Thr Trp Asp
Cys Trp Cys Ile
C23H33N5O5S2 (523.1923008000001)
Cys Trp Cys Leu
C23H33N5O5S2 (523.1923008000001)
Cys Trp Asp Thr
Cys Trp Glu Ser
Cys Trp Ile Cys
C23H33N5O5S2 (523.1923008000001)
Cys Trp Leu Cys
C23H33N5O5S2 (523.1923008000001)
Cys Trp Ser Glu
Cys Trp Thr Asp
Asp Cys Met Arg
Asp Cys Arg Met
Asp Cys Thr Trp
Asp Cys Trp Thr
Asp Asp Phe Gln
Asp Asp Gln Phe
Asp Glu Phe Asn
Asp Glu Asn Phe
Asp Phe Asp Gln
Asp Phe Glu Asn
Asp Phe Asn Glu
Asp Phe Gln Asp
Asp Met Cys Arg
Asp Met Met Gln
C19H33N5O8S2 (523.1770458000001)
Asp Met Gln Met
C19H33N5O8S2 (523.1770458000001)
Asp Met Arg Cys
Asp Asn Glu Phe
Asp Asn Phe Glu
Asp Gln Asp Phe
Asp Gln Phe Asp
Asp Gln Met Met
C19H33N5O8S2 (523.1770458000001)
Asp Arg Cys Met
Asp Arg Met Cys
Asp Thr Cys Trp
Asp Thr Trp Cys
Asp Trp Cys Thr
Asp Trp Thr Cys
Glu Cys Ser Trp
Glu Cys Trp Ser
Glu Asp Phe Asn
Glu Asp Asn Phe
Glu Phe Asp Asn
Glu Phe Asn Asp
Glu Met Met Asn
C19H33N5O8S2 (523.1770458000001)
Glu Met Asn Met
C19H33N5O8S2 (523.1770458000001)
Glu Asn Asp Phe
Glu Asn Phe Asp
Glu Asn Met Met
C19H33N5O8S2 (523.1770458000001)
Glu Ser Cys Trp
Glu Ser Trp Cys
Glu Trp Cys Ser
Glu Trp Ser Cys
Phe Asp Asp Gln
Phe Asp Glu Asn
Phe Asp Asn Glu
Phe Asp Gln Asp
Phe Glu Asp Asn
Phe Glu Asn Asp
Phe Asn Asp Glu
Phe Asn Glu Asp
Phe Gln Asp Asp
Gly Met Met Trp
C23H33N5O5S2 (523.1923008000001)
Gly Met Trp Met
C23H33N5O5S2 (523.1923008000001)
Gly Trp Met Met
C23H33N5O5S2 (523.1923008000001)
His Cys His Gln
His Cys Gln His
His His Cys Gln
His His Gln Cys
His Gln Cys His
His Gln His Cys
Ile Cys Cys Trp
C23H33N5O5S2 (523.1923008000001)
Ile Cys Trp Cys
C23H33N5O5S2 (523.1923008000001)
Ile Trp Cys Cys
C23H33N5O5S2 (523.1923008000001)
Leu Cys Cys Trp
C23H33N5O5S2 (523.1923008000001)
Leu Cys Trp Cys
C23H33N5O5S2 (523.1923008000001)
Leu Trp Cys Cys
C23H33N5O5S2 (523.1923008000001)
Met Cys Asp Arg
Met Cys Arg Asp
Met Asp Cys Arg
Met Asp Met Gln
C19H33N5O8S2 (523.1770458000001)
Met Asp Gln Met
C19H33N5O8S2 (523.1770458000001)
Met Asp Arg Cys
Met Glu Met Asn
C19H33N5O8S2 (523.1770458000001)
Met Glu Asn Met
C19H33N5O8S2 (523.1770458000001)
Met Gly Met Trp
C23H33N5O5S2 (523.1923008000001)
Met Gly Trp Met
C23H33N5O5S2 (523.1923008000001)
Met Met Asp Gln
C19H33N5O8S2 (523.1770458000001)
Met Met Glu Asn
C19H33N5O8S2 (523.1770458000001)
Met Met Gly Trp
C23H33N5O5S2 (523.1923008000001)
Met Met Asn Glu
C19H33N5O8S2 (523.1770458000001)
Met Met Gln Asp
C19H33N5O8S2 (523.1770458000001)
Met Met Trp Gly
C23H33N5O5S2 (523.1923008000001)
Met Asn Glu Met
C19H33N5O8S2 (523.1770458000001)
Met Asn Met Glu
C19H33N5O8S2 (523.1770458000001)
Met Gln Asp Met
C19H33N5O8S2 (523.1770458000001)
Met Gln Met Asp
C19H33N5O8S2 (523.1770458000001)
Met Arg Cys Asp
Met Arg Asp Cys
Met Trp Gly Met
C23H33N5O5S2 (523.1923008000001)
Met Trp Met Gly
C23H33N5O5S2 (523.1923008000001)
Asn Asp Glu Phe
Asn Asp Phe Glu
Asn Glu Asp Phe
Asn Glu Phe Asp
Asn Glu Met Met
C19H33N5O8S2 (523.1770458000001)
Asn Phe Asp Glu
Asn Phe Glu Asp
Asn Met Glu Met
C19H33N5O8S2 (523.1770458000001)
Asn Met Met Glu
C19H33N5O8S2 (523.1770458000001)
Gln Cys His His
Gln Asp Asp Phe
Gln Asp Phe Asp
Gln Asp Met Met
C19H33N5O8S2 (523.1770458000001)
Gln Phe Asp Asp
Gln His Cys His
Gln His His Cys
Gln Met Asp Met
C19H33N5O8S2 (523.1770458000001)
Gln Met Met Asp
C19H33N5O8S2 (523.1770458000001)
Arg Cys Asp Met
Arg Cys Met Asp
Arg Asp Cys Met
Arg Asp Met Cys
Arg Met Cys Asp
Arg Met Asp Cys
Ser Cys Glu Trp
Ser Cys Trp Glu
Ser Glu Cys Trp
Ser Glu Trp Cys
Ser Trp Cys Glu
Ser Trp Glu Cys
Thr Cys Asp Trp
Thr Cys Trp Asp
Thr Asp Cys Trp
Thr Asp Trp Cys
Thr Trp Cys Asp
Thr Trp Asp Cys
Trp Cys Cys Ile
C23H33N5O5S2 (523.1923008000001)
Trp Cys Cys Leu
C23H33N5O5S2 (523.1923008000001)
Trp Cys Asp Thr
Trp Cys Glu Ser
Trp Cys Ile Cys
C23H33N5O5S2 (523.1923008000001)
Trp Cys Leu Cys
C23H33N5O5S2 (523.1923008000001)
Trp Cys Ser Glu
Trp Cys Thr Asp
Trp Asp Cys Thr
Trp Asp Thr Cys
Trp Glu Cys Ser
Trp Glu Ser Cys
Trp Gly Met Met
C23H33N5O5S2 (523.1923008000001)
Trp Ile Cys Cys
C23H33N5O5S2 (523.1923008000001)
Trp Leu Cys Cys
C23H33N5O5S2 (523.1923008000001)
Trp Met Gly Met
C23H33N5O5S2 (523.1923008000001)
Trp Met Met Gly
C23H33N5O5S2 (523.1923008000001)
Trp Ser Cys Glu
Trp Ser Glu Cys
Trp Thr Cys Asp
Trp Thr Asp Cys
8-chloro-11-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridine,trihydrochloride
C26H29Cl4N3 (523.1115474000001)
Butyl 2-[[3-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-hydroxy-1-naphthyl]azo]benzoate
N-(p-chlorophenyl)-2-cyano-2-[2,3-dihydro-3-[tetrahydro-2,4,6-trioxo-1-p-tolylpyrimidin-5(2H)-ylidene]-1H-isoindol-1-ylidene]acetamide
Sarecycline hydrochloride
C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic D003879 - Dermatologic Agents
5-[6,8-bis(phenylsulfanyl)-1H-benzo[cd]indol-2-ylidene]-1,3-dimethyl-1,3-diazinane-2,4,6-trione
COPPER(II) 3,5-DIISOPROPYLSALICYLATE HYDRATE
C26H36CuO7 (523.1756895999999)
Sitagliptin phosphate monohydrate
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
Idoxifene
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
Ibiglustat L-malate
C471 - Enzyme Inhibitor Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
(6R,7R)-3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(10R)-6-carboxy-10-[(9R)-4,5-dihydroxy-2-(hydroxymethyl)-10-oxo-9H-anthracen-9-yl]-8-hydroxy-9-oxo-10H-anthracen-1-olate
3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
N-[3-[3-(1-piperidinylsulfonyl)anilino]-2-quinoxalinyl]benzenesulfonamide
C25H25N5O4S2 (523.1347890000001)
Asp-Phe-Asp-Gln
A tetrapeptide composed of L-aspartic acid, L-phenylalanine, L-aspartic acid and L-glutamine joined in sequence by peptide linkages.
[2-(4-Naphthalen-2-ylsulfonylpiperazin-1-yl)-2-oxoethyl] 2-[(3,5-dimethylbenzoyl)amino]acetate
N-[3-(1-azepanylsulfonyl)phenyl]-2-[4-(1H-indol-3-ylmethyl)-2,5-dioxo-1-imidazolidinyl]acetamide
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[4-(trifluoromethyl)phenyl]carbamoylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
4,4,4-trifluoro-N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide
4,4,4-trifluoro-N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide
4,4,4-trifluoro-N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
5-chloro-N-[(2R)-2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]-2-hydroxypropyl]-2-methoxybenzamide
C24H30ClN3O6S (523.1543750000001)
Ninerafaxstat (trihydrochloride)
Ninerafaxstat (IMB-1018972) trihydrochloride is a novel mitotropic agent. Ninerafaxstat trihydrochloride increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat trihydrochloride can be used for the research of cardiovascular diseases[1].
(e,2z)-2-{[(2s)-2-amino-3-(3,4-dihydroxyphenyl)-1-hydroxypropylidene]amino}-n-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-3-(3,4,5-trihydroxyphenyl)prop-2-enimidic acid
19-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione
[(3s,4r,5s)-5-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[4-(hydroxymethyl)phenoxy]oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl pyridine-2-carboxylate
[(10-methanesulfonyl-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}decylidene)amino]oxysulfonic acid
(3s,6s)-19-{[(2s,4r,5r,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione
methyl 4-hydroxy-8-(hydroxymethyl)-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-3h-pyrrolo[3,2-e]indole-2-carboxylate
methyl (1s,3r,4s,5r,7r,9r,11s,12s,13s)-5-(6-aminopurin-9-yl)-1,12-dihydroxy-4-methoxy-13-[(2-methylpropanoyl)oxy]-2,6,10-trioxatricyclo[7.4.0.0³,⁷]tridecane-11-carboxylate
[(z)-(10-methanesulfonyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}decylidene)amino]oxysulfonic acid
6,20-difluoro-14-hydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),13,17(22),18,20-decaen-12-one
C26H19F2N3O7 (523.1191008000001)
(3s,6r)-19-{[(2s,4r,5r,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione
7,19-difluoro-14-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),13,17(22),18,20-decaen-12-one
C26H19F2N3O7 (523.1191008000001)
[(3s,4r,5s)-5-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[4-(hydroxymethyl)phenoxy]oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl pyridine-3-carboxylate
(2s)-2-{[(2s)-2-{[(2s)-2-{[(2s)-2-amino-3-carboxy-1-hydroxypropylidene]amino}-1-hydroxy-3-phenylpropylidene]amino}-3-carboxy-1-hydroxypropylidene]amino}-4-(c-hydroxycarbonimidoyl)butanoic acid
2-amino-3-(3,4-dihydroxyphenyl)-n-(1-{[2-(3,4-dihydroxyphenyl)ethenyl]carbamoyl}-2-(3,4,5-trihydroxyphenyl)eth-1-en-1-yl)propanimidic acid
methyl (2r)-4-hydroxy-8-(hydroxymethyl)-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-3h-pyrrolo[3,2-e]indole-2-carboxylate
6,20-difluoro-14-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),13,17(22),18,20-decaen-12-one
C26H19F2N3O7 (523.1191008000001)
7,19-difluoro-14-hydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),13,17(22),18,20-decaen-12-one
C26H19F2N3O7 (523.1191008000001)